Allan Wailoo1, Monica Hernández2, Ceri Philips3, Sinead Brophy4, Stefan Siebert5. 1. School of Health and Related Research, University of Sheffield, Sheffield, UK. Electronic address: a.j.wailoo@sheffield.ac.uk. 2. School of Health and Related Research, University of Sheffield, Sheffield, UK. 3. College of Human and Health Sciences, Swansea University, Swansea, Wales, UK. 4. College of Medicine, Swansea University, Swansea, Wales, UK. 5. Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK.
Abstract
OBJECTIVES: Cost-effectiveness analyses of technologies for patients with ankylosing spondylitis frequently require estimates of health utilities as a function of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI). METHODS: Linear regression, bespoke mixture models, and generalized ordered probit models were used to model the EuroQol five-dimensional questionnaire as a function of BASDAI and BASFI. Data were drawn from a large UK cohort study (n = 516 with up to five observations) spanning the full range of disease severity. RESULTS: Linear regression was systematically biased. Three- and four-component mixture models and generalized probit models exhibit no such bias and improved fit to the data. The mean, median, mean error, and mean absolute error favored the mixture model approach. Root mean square error favored the generalized ordered probit model approach for the data as a whole. Model fit assessed using these same measures by disease severity quartiles tended to be best using the mixture models. The value of moving from good to poor health may differ substantially according to the chosen method. Simulated data from the mixture and probit models yield a very similar distribution to the original data set. CONCLUSIONS: These results add to a body of evidence that the statistical model used to estimate health utilities matters. Linear models are not appropriate. The four-class bespoke mixture model approach provides the best performing method to estimate the EuroQol five-dimensional questionnaire values from BASDAI and BASFI.
OBJECTIVES: Cost-effectiveness analyses of technologies for patients with ankylosing spondylitis frequently require estimates of health utilities as a function of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI). METHODS: Linear regression, bespoke mixture models, and generalized ordered probit models were used to model the EuroQol five-dimensional questionnaire as a function of BASDAI and BASFI. Data were drawn from a large UK cohort study (n = 516 with up to five observations) spanning the full range of disease severity. RESULTS: Linear regression was systematically biased. Three- and four-component mixture models and generalized probit models exhibit no such bias and improved fit to the data. The mean, median, mean error, and mean absolute error favored the mixture model approach. Root mean square error favored the generalized ordered probit model approach for the data as a whole. Model fit assessed using these same measures by disease severity quartiles tended to be best using the mixture models. The value of moving from good to poor health may differ substantially according to the chosen method. Simulated data from the mixture and probit models yield a very similar distribution to the original data set. CONCLUSIONS: These results add to a body of evidence that the statistical model used to estimate health utilities matters. Linear models are not appropriate. The four-class bespoke mixture model approach provides the best performing method to estimate the EuroQol five-dimensional questionnaire values from BASDAI and BASFI.
Authors: Mónica Hernández Alava; Allan Wailoo; Stephen Pudney; Laura Gray; Andrea Manca Journal: Health Technol Assess Date: 2020-06 Impact factor: 4.014
Authors: Paul Emery; Marjolijn Van Keep; Steve Beard; Chris Graham; LaStella Miles; Steffen Marc Jugl; Praveen Gunda; Anna Halliday; Helena Marzo-Ortega Journal: Pharmacoeconomics Date: 2018-08 Impact factor: 4.981
Authors: Gian Luca Di Tanna; Joshua K Porter; Richard B Lipton; Anthony J Hatswell; Sandhya Sapra; Guillermo Villa Journal: Health Qual Life Outcomes Date: 2019-11-12 Impact factor: 3.186